Company news

BetterLife Pharma Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

BetterLife Pharma Engages Market Maker

November 20, 2026

BetterLife Pharma Announces New Preclinical Research Highlighting Neuroplasticity-Related Effects of Non-Hallucinogenic BETR-001 at Neuroscience 2026

November 17, 2026

BetterLife Pharma Announces Stock Option Grant

November 17, 2026

BetterLife Pharma Announces Settlement of Claim with Dr. Steven Sangha

November 6, 2026

2026-11-05 BETR – Board Changes FINAL

November 5, 2026

BetterLife Pharma Appoints Henry Chow, CPA, CA, to Board of Directors

November 5, 2026

BetterLife Pharma Appoints LifeSci Advisors as Investor Relations Firm

October 27, 2026

BetterLife Pharma Appoints Professor Richard B. Lipton as Co-Chair of its Scientific Advisory Board

October 19, 2026

BetterLife Pharma Appoints Sheila Leitzinger as Head of Clinical Operations

October 15, 2026

BetterLife Pharma Establishes Scientific Advisory Board for Headache Program; Professor Peter Goadsby Appointed Co-Chair

October 14, 2026

BetterLife Pharma Addresses Notice of Civil Claim Filed by Steven Sangha

October 9, 2026

BetterLife Pharma Announces Rescheduling and Reclassification of Annual General Meeting to Annual General and Special Meeting

September 29, 2026

BetterLife Pharma Inc. Announces Closing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants

September 17, 2026

BetterLife Pharma Inc. Announces Filing of Final Prospectus for US$100 Million Public Offering of Common Shares and Pre-Funded Warrants

September 11, 2026

BetterLife Pharma Appoints Charles Duncan as Director and Chair of the Audit Committee

August 31, 2026

BetterLife Pharma Inc. Announces Pricing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants

August 28, 2026

BetterLife Pharma Inc. Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants

August 24, 2026

BetterLife Pharma Appoints Mahan Chehrenama, DO, as Chief Medical Officer

August 19, 2026

BetterLife Pharma Prioritizes BETR-001 to Lead in Migraine and Headache Disorders, Targeting a Clinically Validated, FDA-Precedented Serotonergic Mechanism

July 13, 2026

BetterLife Pharma Announces Appointment of John W. LaRocca to Board of Directors and Audit Committee

July 9, 2026

BetterLife Engages Nucro-Technics to Complete the last GLP Toxicology Study of BETR-001 Required by the FDA for IND and Phase 1

July 6, 2026

BetterLife Engages Syner-G to Oversee GMP Manufacturing of BETR-001 for IND and Phase 1

June 25, 2026

BetterLife Pharma Secures CAD $2 Million in New Capital to Complete BETR-001 FDA IND Filing

June 22, 2026

Annual Report for Fiscal Year Ending January 31, 2026 (Form 20-F)

June 1, 2026

BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director

May 13, 2026

BetterLife Pharma to Participate in YAFO Capital Access Asia Partnering Forum During JPM Week in San Francisco

January 6, 2026

BetterLife Pharma Announces Engagement with Shanghai-Based YAFO Capital

December 11, 2025

BetterLife Pharma Highlights Advantages of BETR-001 -- a Potent Neuroplastogen

December 4, 2025

BetterLife Pharma Highlights Advantages of BETR-001 - a Potent Neuroplastogen

December 4, 2025

BetterLife Pharma Welcomes Daniel Carcillo as Corporate Advisor

November 25, 2025

BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor

October 22, 2025

USPTO Files ISSUE NOTIFICATION for BetterLife's BETR-001 Composition of Matter Patent

June 18, 2025

BetterLife Pharma Provides Scientific Update on Neuroplastogenic Activity of BETR-001

May 28, 2025

BetterLife Provides Comments on CEO’s Share Position Ownership and Recent BCSC Press Release

May 22, 2025

BetterLife Pharma Provides Scientific Update of Mechanism of Action of BETR-001 in Treatment of Psychiatric Disorders

May 14, 2025

BetterLife Announces Debt Settlements

May 6, 2025

BetterLife Pharma Appoints Corporate Advisor

April 3, 2025

BetterLife Pharma Appoints New Director

March 31, 2025

BetterLife Announces Debt Conversions

March 10, 2025

BetterLife Pharma Inc. to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

April 15, 2024

BetterLife Pharma to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

April 24, 2023

BetterLife Pharma: Invitation to the Benzinga Global Small Cap Conference

October 25, 2021

KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing

October 18, 2021

KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th

October 11, 2021

April Psychedelic Capital Investigates Clinical Trials & Real World Evidence & Going Mainstream: Mass Adoption

April 28, 2021

Horizons ETFs Completes Rebalance of World's First Psychedelics ETF

March 26, 2021

BetterLife Enters Into Research Agreement with UCSD for TD-0148A Behavioural Pharmacology Studies

March 24, 2021

CSE Bulletin: Fundamental Change - BetterLife Pharma Inc. (BETR)

August 31, 2020

BetterLife Pharma Provides Update on Proposed Acquisition of Altum and its Regulatory Guidance and Updated Clinical Development Plan

July 27, 2020

BetterLife Pharma Announces Consolidation of its Common Shares

June 24, 2020

Older news releases →

Decks